economic evaluation of sq-standardized grass allergy immunotherapy tablet (grazax®) in children

Clicks: 260
ID: 183084
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #40 of 51 articles by views in TheScientificWorldJournal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Sarah Ronaldson,1 Matthew Taylor,1 Peter G Bech,2 Ruth Shenton,1 Albrecht Bufe3 1York Health Economics Consortium, York, UK; 2ALK-Abelló A/S, Hørsholm, Denmark; 3Ruhr-Universität Bochum, Bochum, Germany Background: Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The objective of this study was to provide an economic assessment of whether treatment with the SQ-standardized grass AIT, Grazax® (Phleum pratense) in combination with symptomatic medications is preferable to the standard of care using symptomatic medications only. The analysis was performed for children with grass pollen-induced rhinoconjunctivitis, with or without concomitant asthma, in the UK. Methods: The model evaluated the two treatment regimens in a cohort of 1,000 children from a payer’s perspective. Treatment was modeled in terms of management of symptoms, impact on resource use, and development of allergic asthma. The analysis modeled the use of SQ-standardized grass AIT and the sustained effects of treatment over a 9-year time horizon (ie, 3 years of treatment, with modeled long-term benefits). Data inputs were drawn from a recent clinical trial, published studies, and databases. Results: SQ-standardized grass AIT improves patient outcomes, generating an incremental cost per quality-adjusted life year gained of £12,168. This is below commonly accepted thresholds in the UK. Conclusion: The resulting incremental cost per QALY falls below commonly accepted willingness to pay thresholds. Therefore, the SQ-standardized grass AIT is a cost-effective option for the treatment of grass pollen-induced rhinoconjunctivitis in the UK pediatric population. Keywords: cost-effectiveness, cost, quality of life, cost-benefit, United Kingdom, rhinoconjunctivitis, infant
Reference Key
s2014clinicoeconomicseconomic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A
Are you one of these authors? Claim your profile
Journal TheScientificWorldJournal
Year 2014
DOI
DOI not found
URL
http://www.dovepress.com/economic-evaluation-of-sq-standardized-grass-allergy-immunotherapy-tab-a16384
Keywords
pharmacology medicine (general)therapeutics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.